Replies to post #82364 on Biotech Values

[gophie]

The timing of the BPAX’s two PR’s—8am ET for the clinical data and 2:16pm ET for the financing—allowed investors who bought into the financing to short BPAX with abandon all morning and half the afternoon.

I can see why these investors short the shares to a tune of up to 6 million shares. But I have a hard time understanding who on the other side of the trades are buying and paying up to 51% more for these shares when the 50-Day Moving Average is $1.77 and the 200-Day Moving Average is $1.81.
Even the short position of 622,000 shares cannot explain this kind of volume.